in high-risk disease sequential methotrexate/dactinomycin , methotrexate plus dactinomycin plus cyclophosphamide or chlorambucil , or methotrexate plus 6-mercaptopurine , or a combination protocol consisting of cyclophosphamide , hydroxyurea , dactinomycin , methotrexate , vincristine ( vcr ) , folinic acid , and doxorubicin ( chamoca ) produce complete remission rates in 70 to 80 percent of patients .
C0025677
methotrexate
C0279969
chamoca